CIRIUM
20.3.2023 09:01:31 CET | Business Wire | Press release
Cirium, the aviation analytics leader, has launched the aviation industry’s first Airline Routes tool to identify actual flights flown by aircraft type.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230320005187/en/
Cirium's Airline Routes tool analyzes an airline's routes using satellite-based flight tracking data to identify actual flights flown by aircraft type. (Photo: Business Wire)
It uses applied analytics to derive routes flown by airlines based on satellite-based flight tracking and fuses this with advanced fleet data.
The new premium Routes tool is part of Ascend Profiles, a visual descriptive analytics tool which enables businesses to quickly view aircraft intelligence by airline or lessor.
Businesses such as aircraft lessors, banks or aircraft manufacturers are empowered to identify the aircraft flown by route for 1,700 airlines and factor development opportunities or risk into their decision making.
By leveraging satellite-based flight tracking data the tool identifies what routes and aircraft airlines actually flew rather than what they planned to fly providing the most accurate flight completion picture.
Kevin Hightower, Cirium VP of Product said: “The Airline Routes tool is the first of its kind to bring together such advanced data – the satellite-based flight tracking and the comprehensive fleet data – meaning businesses can conduct quick yet accurate due diligence on an airline portfolio.
“Understanding which aircraft an airline is actually flying and on what routes is critical to identify where aircraft demand may be and whether an airline is growing or reducing their network.”
India is one of the markets in the spotlight currently, as air travel is helping to boost economic growth in the region. Low-cost-carrier, IndiGo recently announced it was looking to grow its international network and further solidify its domestic operations.
According to Ascend Profiles, IndiGo has a fleet of 306 aircraft – (273 in service and 33 in storage), plus 501 on order. Of the delivered fleet, 36% are on operating lease.
The Routes tool shows which two-way international routes IndiGo was operating this January which it was not in January 2022. For example, 172 flights were tracked on the newly added route between Indira-Gandhi International Airport in Delhi to Tribhuvan International in Kathmandu. All operated using Airbus A320s.
Additionally, the new tool shows the bi-directional routes for which IndiGo has ramped up operations. The carrier saw the most significant growth on the Singapore – Bengaluru route, where it completed 62 flights, all using A320s, this January versus only one flight, using an A321, last January.
IndiGo also substantially increased its operations this year on the Dubai – Ahmedabad route, completing five times the number of flights in Jan 23 when compared with Jan 22.
The Airline Routes tool is part of Ascend Profiles which visualizes aircraft intelligence of airline or lessor profiles and provides quick and accurate insights showing the latest 12-month year-over-year flights flown by an airline’s routes and can be viewed by flights, seats and ASKs. The tool is available as a web-app on desktop, tablet, and mobile. Find out more.
Notes to editors
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit cirium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005187/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 08:00:00 CEST | Press release
A hybrid quantum-classical algorithm, executed end to end on IQM hardware, produced feasible schedules with Deutsche Bahn, the German rail operator, using a real operational dataset of 190 trips across five German cities. The approach runs on today’s hardware and is designed to improve automatically as quantum processors scale, offering enterprises a model for extracting value now, ahead of fault-tolerant computing. The collaboration reflects IQM’s push into enterprise adoption. The company has sold 24 quantum computers worldwide and listed on the Nasdaq Global Select Market and Nasdaq Helsinki in July 2026 under the ticker IQMX. IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.busines
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 07:00:00 CEST | Press release
Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent la
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom